Thus, the mechanism of anti-CD38 novel agent may suggest that they possess an outstanding effect on tumor cells than other traditional regimens in triplet regimens for RRMM and single regimen for heavily pretreated MM patients. Here, CD38 is linked to Miyoshi myopathy.